The University of Texas MD Anderson Cancer Center / National Cancer Institute / Yale Cancer Center / University of Colorado / /
IndustryTerm
Therapy for Lung Cancer / therapy for each type of cancer / care for patients with lung cancer / pharmaceutical / treatment of lung cancer / registration protocol / Therapies for Lung Cancer / therapies for squamous cell cancer / pharmaceutical partners / /
MedicalCondition
advanced disease / colorectal cancer / lung cancer PRO / melanoma / advanced-stage lung squamous cell carcinoma / non-small cell lung cancer / squamous cell cancer / breast cancer / homogeneous cancer / cancers / tumor / squamous cell lung cancer / cancer / disease / such incurable cancer / pain / lung cancer / future lung cancer / /
MedicalTreatment
immunotherapies / chemotherapy / immunotherapy / drug therapy / /
Organization
National Cancer Institute / Foundation for the National Institutes of Health / Thoracic Malignancy Steering Committee / Food and Drug Administration / Oversight Committee / Yale / Yale Cancer Center / University of Colorado / Drug Selection Committee / Energy and Commerce Subcommittee / United States House of Representatives / European Medicines Agency / Clinical Trials Testimony Before Committee on Energy / Commerce Subcommittee / FDA / American Cancer Society / NCI NCTN / University of Texas / /
Person
Vassiliki Papadimitrakopoulou / Jeff Allen / David Gandara / Upton / Roy Herbst / Pallone / Jeff Abrams / Fred Hirsch / Vali Papadimitrakopoulou / Mary Redman / Ellen Sigal / Charles Blanke / /
Position
Professor of Medicine and Chief / Ensign / specialist / Cancer Center Co-Chair / Chairman / Director for Translational Research / model for future trials / /
Product
FOCUS4 / New Therapies / /
ProvinceOrState
Texas / Maryland / Colorado / /
PublishedMedium
Cancer Research / /
Technology
pre-defined algorithm / chemotherapy / phase II/III registration protocol / drug development / /